Download PDF
Thromb Haemost 2007; 98(05): 1148-1150
DOI: 10.1160/TH07-05-0348
Letters to the Editor
Schattauer GmbH

Anticoagulation quality and the risk of recurrence of venous thromboembolism

Daniela Poli
1   Department of Medical and Surgical Critical Care, Thrombosis Centre, Azienda Ospedaliero- Universitaria Careggi, Florence, Italy
,
Emilia Antonucci
1   Department of Medical and Surgical Critical Care, Thrombosis Centre, Azienda Ospedaliero- Universitaria Careggi, Florence, Italy
,
Gabriele Ciuti
1   Department of Medical and Surgical Critical Care, Thrombosis Centre, Azienda Ospedaliero- Universitaria Careggi, Florence, Italy
,
Rosanna Abbate
1   Department of Medical and Surgical Critical Care, Thrombosis Centre, Azienda Ospedaliero- Universitaria Careggi, Florence, Italy
,
Domenico Prisco
1   Department of Medical and Surgical Critical Care, Thrombosis Centre, Azienda Ospedaliero- Universitaria Careggi, Florence, Italy
› Author Affiliations
Further Information

Publication History

Received 14 May 2007

Accepted after resubmission 15 August 2007

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Christiansen SC, Cannegieter SC, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
    CrossrefPubMedGoogle Scholar
  • 2 Baglin T. Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: not yet. J Thromb Haemost 2006; 4: 2530-2532.
    CrossrefPubMedGoogle Scholar
  • 3 Palareti G, Legnani C, Cosmi B. et al. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 2005; 3: 955-961.
    CrossrefPubMedGoogle Scholar
  • 4 Prandoni P, Hutten BA, van Dongen CJ. et al. Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep venous thrombosis. J Thromb Haemost. 2007 Epub ahead of print.
    PubMedGoogle Scholar
  • 5 Gadisseur AP, Christiansen SC, van der Meer FJ. et al. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study (LETS). J Thromb Haemost 2007; 5: 931-936.
    CrossrefPubMedGoogle Scholar
  • 6 Italian Federation of Anticoagulation Clinics.. A guide to Oral Anticoagulant Therapy. Haemostasis 1998; 28 (Suppl. 01) 1-46.
    PubMedGoogle Scholar
  • 7 Buller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
    CrossrefPubMedGoogle Scholar
  • 8 Mariani G, Manotti C, Dettori AG. A computerized regulation of dosage in oral anticoagulant therapy. Res Clin Lab 1990; 20: 119-125.
    PubMedGoogle Scholar
  • 9 Rosendaal FR, Cannegieter SC, van der Meer FJM. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Poli D, Antonucci E, Cecchi E. et al. Clotting activation after oral anticoagulant therapy discontinuation: a risk factor for recurrent venous thromboembolism. Blood Coagul Fibrinolysis 2004; 15: 221-225.
    CrossrefPubMedGoogle Scholar